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Background: Type 2 chronic rhinosinusitis (CRS), especially eosinophilic CRS (ECRS), is an intractable
upper airway inflammatory disease. Establishment of serum biomarkers reflecting the pathophysiology
of CRS is desirable in a clinical setting. As IgG4 production is regulated by type 2 cytokines, we sought to
determine whether serum IgG4 levels can be used as a biomarker for CRS.
Methods: Association between the serum IgG4 levels and clinicopathological factors was analyzed in 336
CRS patients. Receiver operating characteristics (ROC) analysis was performed to determine the cut-off
value of serum IgG4 levels that can be used to predict the post-operative recurrence.
Results: Serum IgG4 levels were significantly higher in patients with moderate to severe ECRS versus
those with non to mild ECRS. The levels were also significantly higher in asthmatic patients and patients
exhibiting recurrence after surgery compared to controls. ROC analysis determined that the best cut-off
value for the serum IgG4 level to predict the post-operative recurrence was 95 mg/dL. The corresponding
sensitivity and specificity were 39.7% and 80.5%, respectively. When we combined the two cut-off values
for the serum IgG4 and periostin, patients with high serum levels of either IgG4 or periostin exhibited a
high post-operative recurrence (OR: 3.95) as compared to patients having low serum levels of both IgG4
and periostin.
Conclusions: The present results demonstrate that the serum IgG4 level is associated with disease
severity and post-operative course in CRS. In particular, the combination of serum IgG4 and periostin
could be a novel biomarker that predicts post-operative recurrence.
Copyright © 2019, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).yngology, International University of Health and Welfare Graduate School of Medicine, Narita, Japan.
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survey of refractory eosinophilic chronic
rhinosinusitis; NP, nasal polyps;
NSAIDs, non-steroidal anti-inflammatory
drugs; ROC, receiver operating
characteristicsTable 1
Subject characteristics.
Groups
Number
Age (years old)
Sex (female/male)
Blood eosinophil rate (%)
Serum total IgE (IU/mL)
FEV1/FVC ratio (%)
Comorbidity of Asthma (n)
aspirin-exacerbated respiratory diseases (n)
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Chronic rhinosinusitis (CRS) is a prevalent inflammatory disease
in the upper airway. It has been shown that some phenotypes/
endotypes, especially moderate to severe eosinophilic chronic
rhinosinusitis (ECRS), are comorbid with asthma and refractory to
pharmacotherapy and/or surgery.1,2 Although the precise etiology
and pathophysiology underlying intractable CRS remain poorly
understood, altered humoral immunity, including IgG, IgA, IgD and
IgE, appears to be involved.3e8 For example, we have recently re-
ported that the number of IgG4-positive cells was significantly
higher in nasal polyp (NP), especially in severe ECRS patients, as
compared to that in uncinate tissue. The expression was signifi-
cantly higher in asthmatic patients, especially those with aspirin-
exacerbated respiratory diseases (AERD), versus non-asthmatic
patients. In addition, the number of infiltrating IgG4-positive cells
was significantly higher in patients with a poor post-operative
course (sustained sinus shadow 6 months after surgery) as
compared to patients with a good post-operative course. This
suggests that local expression of IgG4 on cells is associated with the
pathophysiology of CRS, including eosinophilia, asthma comor-
bidity and post-operative course.8
IgG4 is the least abundant IgG subclass in human serum,
comprising approximately 5% of the total IgG.9 The production of
IgG4 is regulated by IL-10 together with a co-stimulatory signal
through CD40/CD40L and type 2 cytokines of IL-4 and IL-13, which
are crucial factors for IgE production.10 It has been reported that
either non-specific or antigen-specific serum IgG4 could potentially
be a biomarker for type 2 inflammatory diseases.8,9 It has also been
established that serum antigen-specific IgG4 is elevated after
allergen immunotherapy.11 Elevation of serum IgG4 has addition-
ally been seen in patients with AERD, nasal polyposis, eosinophilia
and celiac disease.12 Elevated serum total IgG4 has also been re-
ported in patients with IgG4-related diseases (IgG4-RD).13
As previously discussed above, our recent report presented
preliminary results on 17 serum samples that showed a significant
and positive correlation between the numbers of infiltrating IgG4-
positive cells in the tissues and serum levels of IgG4, which sug-
gests that the serum IgG4 level is associated with the severity in
ECRS.8 In addition, we have recently showed that serum level of
periostin, a matricellular protein induced by type 2 cytokines such
as IL-4 and IL-13, increased significantly along with the severity of
ECRS. Post-operative recurrence rate was significantly higher in
patients with high serum periostin level.14,15 In our present study,Non-ECRS
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ps://doi.org/10.1016/j.alit.201we expanded the preliminary study and further analyzed a larger
number of serum samples (n ¼ 336) in order to determine whether
the level of serum IgG4, alone or in combinationwith periostin, can
be used for a biomarker that reflects the pathophysiology of CRS,
including the prediction of the post-operative recurrence.Methods
Patients
Patients with CRS (n ¼ 336) having an indication for and un-
dergoing endoscopic sinus surgery (ESS) were enrolled from 5
university hospitals as per our previously described method.14
Thirteen patients received oral glucocorticoid at serum collection.
CRS and its phenotypes, CRS without nasal polyps (CRSsNP: n¼ 58)
and CRS with nasal polyps (CRSwNP: n ¼ 278) were diagnosed
based on the clinical definition reported by the European Position
Paper on Rhinosinusitis and Nasal Polyps 2012.16 None of the pa-
tients met the diagnostic criteria for IgG4-RD.13 Patients were
divided into non-ECRS (n ¼ 119), mild ECRS (n ¼ 57), moderate
ECRS (n ¼ 94) and severe ECRS (n ¼ 66) groups based on the Jap-
anese Epidemiological Survey of Refractory Eosinophilic Chronic
Rhinosinusitis (JESREC) criteria.1 The characteristics of the subjects
in each group are shown in Table 1. Serum samples were collected
prior to the surgery, and stored at 20 C until use. Post-operative
recurrence was defined by an otorhinolaryngologist as the occur-
rence of the conditionwith NPs or purulent discharge in the middle
meatus for more than 28 days after the surgery as shown by a nasal
endoscope.14 Since oral glucocorticoid treatment is effective for
ECRS andmay decrease the rate of recurrence, a substantial number
of subjects received short-course oral glucocorticoid treatment af-
ter surgery.15 For example, 76 out of 85 patients in one institution
(89.4%) received the treatment subsequent to surgery for pre-
venting post-operative inflammation or when edema formation in
paranasal sinus was occurred during the post-operative period.
Informed consent was obtained from each of the patients. The
ethical committees of the Department of Otorhinolaryngology
Head & Neck Surgery, University of Fukui; Department of Otolar-
yngology - Head & Neck Surgery, Okayama University Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences;
Department of Otolaryngology, Jichi Medical University Saitama
Medical Center; Department of Otorhinolaryngology, Head & Neck
Surgery, Dokkyo Medical University and Department ofMild ECRS Moderate ECRS Severe ECRS
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Fig. 1. Comparison of serum IgG4 levels among the phenotypes of CRS. A: Comparison
between CRSsNP and CRSwNP patients. B: Comparison between non-ECRS and ECRS
patients. C: Comparison among four groups of the non, mild, moderate and severe
ECRS patients. P value was determined by a ManneWhitney U test (A and B) and
Dunn's test (C).
A. Oka et al. / Allergology International xxx (xxxx) xxx 3Otorhinolaryngology, Yokohama City Medical Center approved this
research and study protocol.
Determination of serum IgG4 and periostin
Levels of serum IgG4 were determined using IgG4 Human ELISA
Kit (Thermo Fisher Scientific, Waltham, MA) according to the
manufacturer's instructions. Determination of serum levels of
periostin was performed as per a previously reported method.14
Statistical analysis
Values are given as the median. The nonparametric
ManneWhitney U test was used to compare data between the
groups, and Wilcoxon's signed rank test was used to analyze data
within each group. A KruskaleWallis test followed by a Dunn's test
was used for multiple comparisons. Correlation analyses were
performed using Spearman's rank correlation. Statistical analyses
were performed with GraphPad Prism 6 software (GraphPad Soft-
ware, La Jolla, CA). Receiver operating characteristics (ROC) ana-
lyses were performed to determine the cut-off values for the serum
IgG4 and P-values for sensitivity and specificity. Recurrence-free
curves after surgery were drawn using the KaplaneMeier method
where recurrence-free rate was calculated a percentage of patients
without recurrence in each time point. All values were calculated
using JMP Pro 14.0 (SAS Institute, Cary, NC), while logistic regres-
sion analyses were conducted by STATA 12.1 (StataCorp, College
Station, TX). P-values less than 0.05 (two-tailed) were considered to
be statistically significant.
Results
Comparison of serum IgG4 levels among the phenotypes of CRS
Levels of serum IgG4 were significantly higher in CRSwNP pa-
tients (median: 45.0 mg/dL, n ¼ 278) as compared to the CRSsNP
patients (median: 28.5 mg/dL, n ¼ 58) (P ¼ 0.001; ManneWhitney
U test, Fig. 1A). When we divided patients into non-ECRS and ECRS
groups according to the JESREC criteria, the levels were significantly
higher in the ECRS patients (median: 52.0 mg/dL, n ¼ 217) versus
the non-ECRS patients (median: 31.0 mg/dL, n ¼ 119) (P < 0.001,
Fig. 1B). Similar results were seen when CRSwNP patients were
selected and divided into non-ECRS (median: 34.5 mg/dL, n ¼ 72)
and ECRS (median: 52.0 mg/dL, n ¼ 206) groups (P ¼ 0.029). When
we precisely divided CRS patients into four groups (non, mild,
moderate and severe ECRS), the KruskaleWallis test revealed a
significant difference in the level of the serum IgG4 among these
groups (P < 0.001). Dunn's test further showed that the level was
significantly higher in the moderate (median: 52.5 mg/dL,
P ¼ 0.016) and severe (median: 52.5 mg/dL, P < 0.001) but not the
mild (median: 42.0 mg/dL, P¼ 0.887) ECRS patients as compared to
the non-ECRS (median: 31.0 mg/dL) patients (Fig. 1C). The level was
similar between patients with and without pre-operative oral
glucocorticoid treatment (median: 54.0 vs 42.0 mg/dL, P ¼ 0.415).
Pathophysiological significance of serum IgG4 level in CRS
Subsequently, we then pathophysiologically characterized the
level of serum IgG4 in CRS. There was a significant positive and
weak correlation between the level of serum IgG4 and eosinophils
in the sinonasal tissues (n ¼ 193, r ¼ 0.258, P < 0.001; Fig. 2A). The
level was also weakly albeit significantly and positively correlated
with the peripheral blood eosinophilia (n ¼ 336, r ¼ 0.202,
P < 0.001; Fig. 2B). No statistically significant correlations were
seen between the serum IgG4 level and the serum IgE level (n¼ 96,Please cite this article as: Oka A et al., Serum IgG4 as a biomarker re
rhinosinusitis, Allergology International, https://doi.org/10.1016/j.alit.201r ¼ 0.177, P ¼ 0.084; Fig. 2C) or the FEV1/FVC ratio (n ¼ 101,
r¼0.056, P¼ 0.580; Fig. 2D). Since these datawere collected from
independent 5 university hospitals, some were missing, leading to
unequal numbers of patients. The patients were divided into non-
asthmatic (n ¼ 211) and asthmatic (n ¼ 125) groups. Levels of
serum IgG4 were significantly higher in the asthmatic patients
(median: 57.0 mg/dL) versus the non-asthmatic (median: 37.0 mg/
dL) patients (P < 0.001; Fig. 2E). AERD was seen in 34 cases. Serumflecting pathophysiology and post-operative recurrence in chronic
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Fig. 2. Relationship between the serum IgG4 levels and pathophysiological characterizations of CRS including eosinophilia in the sinonasal tissues (A), peripheral blood eosinophilia
(B), serum IgE level (C) and FEV1/FVC ratio (D). Comparison of serum IgG4 level between non-asthmatic and asthmatic patients (E), and non-ARED and AERD patients (F). P value
was determined by a ManneWhitney U test (E, F).
A. Oka et al. / Allergology International xxx (xxxx) xxx4IgG4 levels were also significantly higher in the AERD (median:
68.5 mg/dL) patients versus the non-AERD (median: 39.5 mg/dL)
patients (P ¼ 0.002; Fig. 2F).Significance of serum IgG4 level on the post-operative recurrence in
CRS
There were 253 patients who could be followed throughout the
post-operative course. There were 58 patients (22.9%) who showed
post-operative recurrence. Serum IgG4 levels were significantly
higher in patients exhibiting recurrence (median: 52.5 mg/dL,
median follow-up period: 40.1 months) as compared to those
without recurrence (median: 37.0 mg/dL, median follow-up period:
12.5 months) (P ¼ 0.011; Fig. 3A).Please cite this article as: Oka A et al., Serum IgG4 as a biomarker re
rhinosinusitis, Allergology International, https://doi.org/10.1016/j.alit.201Next, we used the ROC analysis to assess the possibility of using
serum IgG4 levels as a biomarker for predicting the post-operative
course in patients with CRS. The area under the curve (AUC) was
0.610 (95%CI: 0.528e0.693) (Fig. 3B). This analysis indicated that the
best cut-off for serum IgG4was 95mg/dL based on the best positive
likelihood ratio of 2.05, with the corresponding sensitivity and
specificity to predict the recurrence at 39.7% (95% CI: 27.1e53.4) and
80.5% (95% CI: 74.3e85.8), respectively. With this cut-off value, the
KaplaneMeier plot of the post-operative recurrence showed a sig-
nificant difference between the lowserum IgG4 (less than 95mg/dL,
n ¼ 192) and high serum IgG4 (equal to or more than 95 mg/dL,
n ¼ 61) groups (P ¼ 0.004; log-rank test). In high IgG4 group, a pa-
tient with the longest follow-up period (4.65 years) showed a
recurrence, whereas such a patient in low IgG4 group (follow-up
period: 8.08 years) kept a recurrence-free status (Fig. 3C).flecting pathophysiology and post-operative recurrence in chronic
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Fig. 3. Significance of the serum IgG4 level on the post-operative recurrence in CRS. A:
Comparison of serum IgG4 levels between patients with recurrence and those without
recurrence. B: ROC curve for the serum IgG4 levels that were able to predict the post-
operative course. C: KaplaneMeier plot of post-operative recurrence between the
groups of low (<95 mg/dL: black line) and high (95 mg/dL: red line) serum IgG4. P
value was determined by a ManneWhitney U test.
A. Oka et al. / Allergology International xxx (xxxx) xxx 5Use of serum IgG4 and periostin level for the prediction of post-
operative recurrence of CRSwNP
We have recently reported that when the cut-off value is set at
115.5 ng/ml, serum periostin could be used as a biomarker for the
prediction of post-operative recurrence of CRSwNP.14 Therefore, we
sought to determine whether the simultaneous use of serum IgG4
and periostin levels would improve the prediction. There was few
correlation noted between the serum periostin and IgG4 levels
(r ¼ 0.149, 95% CI: 0.039e0.255, P ¼ 0.006; Fig. 4A). When using
these two cut-off values, the KaplaneMeier plot of the post-
operative recurrence showed there was a significant differencePlease cite this article as: Oka A et al., Serum IgG4 as a biomarker re
rhinosinusitis, Allergology International, https://doi.org/10.1016/j.alit.201between the four groups (low periostin/low IgG4: n ¼ 111, low
periostin/high IgG4: n ¼ 81, high periostin/low IgG4: n ¼ 34, high
periostin/high IgG4: n ¼ 27, P < 0.001; log-rank test, Fig. 4B). Lo-
gistic regression analysis showed that the odds ratio (OR) for a poor
post-operative course was 3.95 (95% CI: 1.97e7.92) in patients
having a high serum level of either periostin or IgG4 as compared to
patients who had a low serum level of both periostin and IgG4
(P < 0.001; Fig. 4C). This relationship essentially remained the same
even after we adjusted for the age and sex (OR ¼ 3.85: 95% CI:
1.92e7.69, P < 0.001), presence of NP and ECRS in addition to age
and sex (OR ¼ 3.57: 95% CI: 1.69e7.14, P < 0.001), and institution
where the ESS was performed in addition to the age, sex, presence
of NP and ECRS (OR ¼ 3.33: 95% CI: 1.56e7.14, P ¼ 0.002).
Discussion
The present study examined the serum IgG4 levels in CRS,
especially ECRS. We found that moderate to severe ECRS exhibited
higher serum IgG4 levels. The level was significantly and positively
correlated with the degree of local and blood eosinophilia. In
addition, the serum IgG4 level was associated with post-operative
recurrence. Furthermore, patients having either a high serum
IgG4 or high serum periostin also exhibited a high post-operative
recurrence as compared to those patients having low serum
levels of both IgG4 and periostin. These results may provide a basis
for the diagnostic use of serum IgG4 together with periostin as a
biomarker for not only confirming the severity of ECRS, but also for
predicting the outcome after surgery.
Serum IgG4 was significantly higher in ECRS patients as
compared with non-ECRS patients. IgG4 production is regulated by
type 2 (IL-4 and IL-13) and regulatory (IL-10) cytokines, all of which
are known to be induced in ECRS.17e20 The precise regulation of
IgG4 production remains unclear. We have recently reported that
the production of IL-10 in response to Staphylococcus aureus
enterotoxin, which is a candidate thought to be involved in the
pathogenesis of ECRS, is lower in patients with ECRS as compared to
those with non-ECRS.20 Thus, the presence of IL-10 but not the
amount of IL-10 may play an important role in the production of
IgG4 in ECRS.
Moderate to severe ECRS patients, as determined by the JESREC
criterion, showed a significant elevation of the serum IgG4 as
compared with the non to mild ECRS patients. This result was
similar to our previous finding that severe ECRS was associated
with an augmented infiltration of IgG4-positive cells into the NP.8 A
positive correlation with the blood/tissue eosinophilia was also
found for both the level of the serum IgG4 and the number of tissue
IgG4-positive cells. Moderate to severe ECRS is categorized as a
designated intractable disease in Japan and thus, patients are able
to use the medical expense support system to cover the cost of
treatments. Although the role of IgG4 in the pathogenesis of CRS
remains unclear, the serum IgG4 level could potentially become a
biomarker that can be used to distinguish the intractable pheno-
type of CRS, which may also be useful as a certification that can be
utilized for determining eligibility for the medical support system.
The possibility that comorbid asthma is associated with the re-
fractory disease in CRS was supported by our finding that asthmatic
CRS patients exhibited a significant elevation of the serum IgG4 as
compared to the non-asthmatic CRS patients.2
The serum IgG4 level was also correlated with the post-
operative recurrence. After we set 95 mg/dL as a cut-off level, we
were able to predict the post-operative recurrence at 39.7% sensi-
tivity and 80.5% specificity. 39.7% of sensitivity may be a low value.
However, we selected this cut-off point based on best positive
likelihood ratio of 2.05. If we increase the sensitivity, specificity
must be decreased. For example, when we set the cut-off point asflecting pathophysiology and post-operative recurrence in chronic
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Fig. 4. Use of serum IgG4 and periostin levels for the prediction of the post-operative recurrence of CRSwNP. A: Correlation between the serum periostin and IgG4 levels. B:
KaplaneMeier plot for post-operative recurrence of the four groups based on the cut-off values of periostin and IgG4, which included low periostin/low IgG4 (black line), low
periostin/high IgG4 (green line), high periostin/low IgG4 (cyan line) and high periostin/high IgG4 (red line). C: Comparison of the number of patients with or without recurrence
after surgery between patients showing both low serum periostin and IgG4 and those showing high periostin and/or high IgG4.
A. Oka et al. / Allergology International xxx (xxxx) xxx625.0 mg/dL, sensitivity and specificity is 81.0 and 33.9%, respec-
tively, where the positive likelihood ratio becomes 1.22. This result
was also similar to our previous finding that the number of IgG4-
positive cells in the NP was correlated with improvement of the
LundeMackay CT grading score after surgery, where the residual
sinus shadow in CT could be predicted at 73.3% sensitivity and
82.5% specificity.8 One of the reasons for the difference in the
sensitivity is related to the difference of the endpoints after the
surgery. The primary endpoint after surgery in the present study
was the post-operative recurrence, which was based on the endo-
scopic results of our previous study that found there was no NP
formation or purulent discharge for more than 28 days. On the
other hand, the post-operative course was defined as poor when
the post-operative CT score was equal to more than half of the pre-
operative scores in the previous study. Although the local expres-
sion of IgG4-positive cells seems to be more sensitive due to a
closer reflection of the local inflammation, serum samples werePlease cite this article as: Oka A et al., Serum IgG4 as a biomarker re
rhinosinusitis, Allergology International, https://doi.org/10.1016/j.alit.201more suitable as a clinical biomarker due to the ease of collecting
samples. Measurement of serum IgG4 is available in clinical settings
in Japan and used to diagnose IgG4-RD.21
In order to predict the post-operative recurrence of CRSwNP, we
have recently reported that serum periostin can be utilized as a
biomarker, when the cut-off value is set to 115.5 ng/ml with 60.7%
sensitivity and 61.9% specificity.14 When we combined the two
serum cut-off values for IgG4 and periostin, patients with high
serum levels of either periostin or IgG4 exhibited a high post-
operative recurrence (OR: 3.95) as compared to those patients
who showed low serum levels of both periostin and IgG4.
Furthermore, the OR was higher than that for the single cut-off
value in IgG4 OR: 2.72 (95% CI: 1.44e5.12) and in periostin OR:
2.80 (95% CI: 1.53e5.12). These results suggest that the combina-
tion use of serum IgG4 and serum periostin might be a more
valuable biomarker for predicting the post-operative course as
compared to when using a single estimation. To avoid anyflecting pathophysiology and post-operative recurrence in chronic
9.12.004
A. Oka et al. / Allergology International xxx (xxxx) xxx 7postoperative recurrence, more precise follow-ups and intensive
post-operative treatments such as biologics may be required in
cases having either a high serum IgG4 or high serum periostin. On
the other hand, the present stud.
In conclusion, our results demonstrated that the serum IgG4
level is associated with disease severity and the post-operative
course in CRS, especially for moderate to severe ECRS. In partic-
ular, the combination of serum IgG4 and periostin might be a po-
tential novel biomarker that can be used to predict the post-
operative course. However, the role of IgG4 in the pathogenesis of
CRS remains unclear and a further study will need to be under-
taken. Since refractory CRS is resistant to conventional pharmaco-
logical treatment and surgery, new treatments that are currently
under development including the use of biologics such as anti-IL-4/
IL-13 receptor antibody may become a treatment option in the
future. Additional studies to determine whether these serum
markers, either alone or in combination, are useful in predicting the
efficacy of new treatments will need to be undertaken.
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